Clinical Trial Detail

NCT ID NCT02105350
Title A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

biliary tract cancer

Therapies

Binimetinib + Gemcitabine + Oxaliplatin

Age Groups: adult

No variant requirements are available.